Literature DB >> 1624545

Growth-stimulating phase of macrophage response to activation: the phenomenon and its implications for tumour growth and immunotherapy.

V B Okulov1, B O Voytenkov, A G Ushmorov, N D Polischuk, S A Gromov.   

Abstract

The dynamics of growth-stimulating and cytotoxic activity of mouse peritoneal macrophages (PMo) in response to in vivo and in vitro bacillus Calmette-Guérin (BCG) or bestatin treatment was studied. It was shown that BCG and bestatin induce cytotoxicity in PMo, and that after the cytotoxic response strong growth-stimulating activity develops. PMo, rendered cytotoxic in vivo and afterwards cultivated in vitro, displayed the same switch from a cytotoxic to a growth-stimulating phase. These results suggest that the growth-stimulating phase is the obligatory PMo response to biological response modifiers (BRM) at least to BCG and bestatin. The growth rate of tumours, transplanted into mice during the cytotoxic phase of the response to BCG, was suppressed, whereas tumours transplanted during the growth-stimulating phase were stimulated. It appears that the development of a growth-stimulating phase after the cytotoxic phase of response to activation by BRM could be one of the reasons for the limited effectiveness of immunotherapy based on the application of macrophage activators.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1624545     DOI: 10.1007/bf01225269

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

Review 1.  The macrophages: effector cell wound repair.

Authors:  D R Knighton; V D Fiegel
Journal:  Prog Clin Biol Res       Date:  1989

2.  Macrophage potentiation of invasive capacity of rat ascites hepatoma cells.

Authors:  M Mukai; K Shinkai; R Tateishi; Y Mori; H Akedo
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

3.  Lymphocyte- and macrophage-derived growth factors.

Authors:  S M Wahl
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

4.  Interleukin 1 from human leukemic monocytes.

Authors:  L B Lachman; L C Shih; D C Brown
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

5.  Eradication of cancer metastasis by tumoricidal macrophages.

Authors:  I J Fidler
Journal:  Adv Exp Med Biol       Date:  1988       Impact factor: 2.622

Review 6.  Current condition and prognosis of tumor immunotherapy: a second opinion.

Authors:  M J Mastrangelo; D Berd; H C Maguire
Journal:  Cancer Treat Rep       Date:  1984-01

7.  TNF-alpha mediated selection of macrophage-resistant gene-regulatory tumor variants.

Authors:  L Remels; A Neirynck; L Brys; E Vercauteren; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1989 Sep-Oct       Impact factor: 5.150

8.  Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping.

Authors:  D A Rappolee; D Mark; M J Banda; Z Werb
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

9.  Growth factors for human tumor clonogenic cells elaborated by macrophages isolated from human malignant effusions.

Authors:  A W Hamburger; C P White
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages.

Authors:  P J Polverini; S J Leibovich
Journal:  Lab Invest       Date:  1984-12       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.